Skip to content

Study · Randomized controlled trial · n = 36 · 2023

3 results

Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial.

Katayoshi T, Uehata S, Nakashima N, Nakajo T, Kitajima N, Kageyama M, Tsuji-Naito K

Scientific reports16 Feb 2023Cited by 47 (Europe PMC)

PMID36797393 (opens in a new tab)PMCIDPMC9935856 (opens in a new tab)DOI10.1038/s41598-023-29787-3 (opens in a new tab)PepBankPUB-36797393
Download PDFPubMedAsk about this study
Jump to 3 results

Summary

Many animal studies have shown that oral administration of the nicotinamide adenine dinucleotide (NAD+) precursor nicotinamide mononucleotide (NMN) prevents the reduction of NAD+ levels in organs and tissues, helping alleviate aging-related diseases. However, there are very few clinical reports of NMN supplementation in humans. Thus, this study aimed to investigate the influence of a 12-week NMN oral supplementation on biochemical and metabolic health parameters. A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day. Among the NAD+ metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group. Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups. Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events. NMN safely and effectively elevated NAD+ metabolism in healthy middle-aged adults. Additionally, NMN supplementation showed potential in alleviating arterial stiffness.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy middle-aged adults, NMN significantly increased serum nicotinamide compared with placebo.

    In plain wordsIn healthy middle-aged adults, NMN increased serum nicotinamide compared with placebo.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    IncreaseSerum nicotinamide
    Study

    n = 36

    Comparator
    placebo
    Outcome group
    Receptor activity and mechanism · Metabolic and weight
    Studied dose
    125 mg twice a day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Among the NAD+ metabolites, the levels of nicotinamide in the serum were significantly higher in the NMN intake group than in the placebo group.
    1 context sentence
    Summary · context
    A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In healthy middle-aged adults, pulse wave velocity tended to fall with NMN, but the between-group difference was not significant.

    In plain wordsIn healthy middle-aged adults, arterial stiffness tended to decrease with NMN, but the difference from placebo was not significant.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    No significant changePulse wave velocity
    Study

    n = 36

    Comparator
    placebo
    Outcome group
    Vascular function · Cardiovascular
    Studied dose
    125 mg twice a day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Pulse wave velocity values indicating arterial stiffness tended to decrease in the NMN intake group. However, no significant difference was found between the two groups.
    1 context sentence
    Summary · context
    A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day.
  3. 03HumanRandomized controlled trialSafety outcome

    In healthy middle-aged adults, long-term NMN was well tolerated and caused no adverse events.

    In plain wordsIn healthy middle-aged adults, NMN was well tolerated and caused no adverse events.

    Peptide
    NMN (nicotinamide mononucleotide)
    Outcome
    Direction not reportedAdverse events and tolerability
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    125 mg twice a day · oral · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Long-term NMN supplementation at 250 mg/day was well tolerated and did not cause adverse events.
    1 context sentence
    Summary · context
    A 12-week randomized, double-blind, placebo-controlled, parallel-group clinical trial was conducted. A total of 36 healthy middle-aged participants received one capsule of either 125 mg NMN or placebo twice a day.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:58 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 12:50 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.